Abiraterone inhibits 3β-hydroxysteroid dehydrogenase: A rationale for increasing drug exposure in castration-resistant prostate cancer

Clinical Cancer Research

Volumn 18, Issue 13, 2012, Pages 3571-3579

  Li, Rui ^a   Evaul, Kristen ^a   Sharma, Kamalesh K ^a   Chang, Kai Hsiung ^a   Yoshimoto, Jennifer ^b   Liu, Jiayan ^b   Auchus, Richard J ^a,b   Sharifi, Nima ^a  

^a UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

^b UNIVERSITY OF MICHIGAN MEDICAL SCHOOL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

3(OR 17)BETA HYDROXYSTEROID DEHYDROGENASE; ABIRATERONE; ANDROGEN RECEPTOR; ANDROSTANOLONE; ANDROSTENEDIOL; ANDROSTENEDIONE; HYDROXYSTEROID DEHYDROGENASE; PRASTERONE; PROSTATE SPECIFIC ANTIGEN; PROTEIN 3BETAHSD1; PROTEIN 3BETAHSD2; PROTEIN FKBP5; PROTEIN TMPRSS2; TESTOSTERONE; TUMOR PROTEIN; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CANCER INHIBITION; CASTRATION RESISTANT PROSTATE CANCER; CELL STRAIN; CELL STRAIN LAPC4; CELL STRAIN LNCAP; CONTROLLED STUDY; DRUG EXPOSURE; ENZYME ACTIVITY; ENZYME INHIBITION; GENE EXPRESSION; HORMONE INHIBITION; HUMAN; HUMAN CELL; IC 50; IN VITRO STUDY; IN VIVO STUDY; MALE; MOUSE; NONHUMAN; ORCHIECTOMY; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN LOCALIZATION; TUMOR XENOGRAFT;

3-HYDROXYSTEROID DEHYDROGENASES; ACTIVE TRANSPORT, CELL NUCLEUS; ANDROSTADIENES; ANDROSTENEDIONE; ANIMALS; ANTINEOPLASTIC AGENTS; CELL LINE, TUMOR; DEHYDROEPIANDROSTERONE; DIHYDROTESTOSTERONE; DRUG RESISTANCE, NEOPLASM; HUMANS; ISOENZYMES; MALE; MICE; MICE, INBRED NOD; MICE, SCID; ORCHIECTOMY; PROSTATIC NEOPLASMS; RECEPTORS, ANDROGEN; TESTOSTERONE; TUMOR BURDEN; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84863304593     PISSN: 10780432     EISSN: 15573265     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-12-0908     Document Type: Article

References (28)

1. Sharifi N, Gulley JL, Dahut WL. Androgen deprivation therapy for prostate cancer. JAMA 2005;294:238-44. (Pubitemid 41043794)
2. Montgomery RB, Mostaghel EA, Vessella R, Hess DL, Kalhorn TF, Higano CS, et al. Maintenance of intratumoral androgens in metastatic prostate cancer: a mechanism for castration-resistant tumor growth. Cancer Res 2008;68:4447-54.
3. Titus MA, Schell MJ, Lih FB, Tomer KB, Mohler JL. Testosterone and dihydrotestosterone tissue levels in recurrent prostate cancer. Clin Cancer Res 2005;11:4653-7. (Pubitemid 41557182)
4. Geller J, Albert J, Loza D, Geller S, Stoeltzing W, de la Vega D. DHT concentrations in human prostate cancer tissue. J Clin Endocrinol Metab 1978;46:440-4. (Pubitemid 8305058)
5. Chang KH, Li R, Papari-Zareei M, Watumull L, Zhao YD, Auchus RJ, et al. Dihydrotestosterone synthesis bypasses testosterone to drive castration-resistant prostate cancer. Proc Natl Acad Sci U S A 2011;108:13728-33.
6. Ryan CJ, Tindall DJ. Androgen receptor rediscovered: the new biology and targeting the androgen receptor therapeutically. J Clin Oncol 2011;29:3651-8.
7. Scher HI, Sawyers CL. Biology of progressive, castration-resistant prostate cancer: directed therapies targeting the androgen-receptor signaling axis. J Clin Oncol 2005;23:8253-61. (Pubitemid 46211563)
8. Knudsen KE, Kelly WK. Outsmarting androgen receptor: creative approaches for targeting aberrant androgen signaling in advanced prostate cancer. Expert Rev Endocrinol Metab 2011;6:483-93.
9. Miller WL, Auchus RJ. The molecular biology, biochemistry, and physiology of human steroidogenesis and its disorders. Endocr Rev 2011;32:81-151.
10. Attard G, Reid AH, Yap TA, Raynaud F, Dowsett M, Settatree S, et al. Phase I clinical trial of a selective inhibitor of CYP17, abiraterone acetate, confirms that castration-resistant prostate cancer commonly remains hormone driven. J Clin Oncol 2008;26:4563-71.
11. de Bono JS, Logothetis CJ, Molina A, Fizazi K, North S, Chu L, et al. Abiraterone and increased survival in metastatic prostate cancer. N Engl J Med 2011;364:1995-2005.
12. Ryan CJ, Smith MR, Fong L, Rosenberg JE, Kantoff P, Raynaud F, et al. Phase I clinical trial of the CYP17 inhibitor abiraterone acetate demonstrating clinical activity in patients with castration-resistant prostate cancer who received prior ketoconazole therapy. J Clin Oncol 2010;28:1481-8.
13. Attard G, Reid AH, Auchus RJ, Hughes BA, Cassidy AM, Thompson E, et al. Clinical and biochemical consequences of CYP17A1 inhibition with abiraterone given with and without exogenous glucocorticoids in castrate men with advanced prostate cancer. J Clin Endocrinol Metab 2012;97:507-16.
14. Mostaghel EA, Marck B, Plymate S, Vessella RL, Balk SP, Matsumoto AM, et al. Resistance to CYP17A1 inhibition with abiraterone in castration resistant prostate cancer: Induction of steroidogenesis and androgen receptor splice variants. Clin Cancer Res 2011;17:5913-25.
15. Cai C, Chen S, Ng P, Bubley GJ, Nelson PS, Mostaghel EA, et al. Intratumoral de novo steroid synthesis activates androgen receptor in castration resistant prostate cancer and is upregulated by treatment with CYP17A1 inhibitors. Cancer Res 2011;71:6503-13.
16. Lorence MC, Murry BA, Trant JM, Mason JI. Human 3β-hydroxysteroid dehydrogenase/D5!4 isomerase from placenta: expression in nonsteroidogenic cells of a protein that catalyzes the dehydrogenation/isomerization of C21 and C19 steroids. Endocrinology 1990;126:2493-8.
17. 4isomerase gene family. Endocr Rev 2005;26:525-82.
18. Evaul K, Li R, Papari-Zareei M, Auchus RJ, Sharifi N. 3b-hydroxysteroid dehydrogenase is a possible pharmacological target in the treatment of castration-resistant prostate cancer. Endocrinology 2010;151:3514-20.
19. Potter GA, Barrie SE, Jarman M, Rowlands MG. Novel steroidal inhibitors of human cytochrome P450 17α (17α-hydroxylase-C17,20-lyase): potential agents for the treatment of prostatic cancer. J Med Chem 1995;38:2463-71.
20. Cai W, Ripin DHB. A practical synthesis of pyridylboranes via magnesium-halogen exchange. Synlett 2002;2:273-4. (Pubitemid 34132723)
21. Lee TC, Miller WL, Auchus RJ. Medroxyprogesterone acetate and dexamethasone are competitive inhibitors of different human steroidogenic enzymes. J Clin Endocrinol Metab 1999;84:2104-10. (Pubitemid 30647041)
22. Cai C, Wang H, Xu Y, Chen S, Balk SP. Reactivation of androgen receptor-regulated TMPRSS2:ERG gene expression in castrationresistant prostate cancer. Cancer Res 2009;69:6027-32.
23. Mizokami A, Koh E, Fujita H, Maeda Y, EgawaM, Koshida K,Honma S, Keller ET, Namiki M. The adrenal androgen androstenediol is present in prostate cancer tissue after androgen deprivation therapy and activates mutated androgen receptor. Cancer Res 2004;64:765-71. (Pubitemid 38120921)
24. Sharifi N. The 5a-androstanedione pathway to dihydrotestosterone in castration-resistant prostate cancer. J Investig Med 2012;60:504-7.
25. van Weerden WM, Bierings HG, van Steenbrugge GJ, de Jong FH, Schroder FH. Adrenal glands of mouse and rat do not synthesize androgens. Life Sci 1992;50:857-61.
26. Barrie SE, Potter GA, Goddard PM, Haynes BP, Dowsett M, Jarman M. Pharmacology of novel steroidal inhibitors of cytochrome P450(17) α (17α-hydroxylase/C17-20 lyase). J Steroid Biochem Mol Biol 1994;50:267-73. (Pubitemid 24309119)
27. Sharifi N. New agents and strategies for the hormonal treatment of castration-resistant prostate cancer. Expert Opin Investig Drugs 2010;19:837-46.
28. Zytiga [package insert]. Toronto,ON, Canada: Patheon Inc.; 2011. Available from: http://www.zytigahcp.com/pdf/prescribing-informationpdf.